1156-99-6

Basic information

• Product Name: 10-hydroxynortriptyline
• Synonyms: 10-hydroxynortriptyline;(11Z)-11-[3-(methylamino)propylidene]-5,6-dihydrodibenzo[2,1-b:2',1'-f][7]annulen-5-ol
• CAS NO: 1156-99-6
• Molecular Formula: C₁₉H₂₁NO
• Molecular Weight: 279.38
• Mol File: 1156-99-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 462.3°Cat760mmHg
• Flash Point: 142.1°C
• Appearance: /
• Density: 1.164g/cm³
• Vapor Pressure: 2.42E-09mmHg at 25°C
• CAS DataBase Reference: 10-hydroxynortriptyline(CAS DataBase Reference)
• NIST Chemistry Reference: 10-hydroxynortriptyline(1156-99-6)
• EPA Substance Registry System: 10-hydroxynortriptyline(1156-99-6)

Safety Data

• Hazardous Substances Data: 1156-99-6(Hazardous Substances Data)

Usage

Metabolite of nortriptyline

10-hydroxynortriptyline is a metabolite of the tricyclic antidepressant medication nortriptyline.

Metabolized by CYP2D6 enzyme

It is formed in the body when nortriptyline is metabolized by the CYP2D6 enzyme.

Similar pharmacological activity

10-hydroxynortriptyline has been found to have similar pharmacological activity to nortriptyline.

Contributes to therapeutic effects

It is also thought to contribute to the therapeutic effects of the medication.

Antidepressant properties

10-hydroxynortriptyline has been shown to have antidepressant properties.

Analgesic properties

It has also been shown to have analgesic properties.

Side effects

10-hydroxynortriptyline is associated with side effects such as drowsiness, dry mouth, and constipation.

Variability in levels

Studies have shown that the levels of 10-hydroxynortriptyline in the body can vary widely between individuals.

Impact on effectiveness and side effects

These differences in levels may impact the effectiveness and side effects of nortriptyline treatment.

InChI:InChI=1/C19H21NO.C4H4O4/c1-20-12-6-11-16-15-8-3-2-7-14(15)13-19(21)18-10-5-4-9-17(16)18;5-3(6)1-2-4(7)8/h2-5,7-11,19-21H,6,12-13H2,1H3;1-2H,(H,5,6)(H,7,8)/b16-11+;2-1-

Upstream product

• 549-18-8 amitriptyline hydrochloride 

Relevant articles and documents

Drug Oxidation by Cytochrome P450BM3: Metabolite Synthesis and Discovering New P450 Reaction Types

There is intense interest in late-stage catalytic C-H bond functionalization as an integral part of synthesis. Effective catalysts must have a broad substrate range and tolerate diverse functional groups. Drug molecules provide a good test of these attributes of a catalyst. A library of P450BM3 mutants developed from four base mutants with high activity for hydrocarbon oxidation produced human metabolites of a panel of drugs that included neutral (chlorzoxazone, testosterone), cationic (amitriptyline, lidocaine) and anionic (diclofenac, naproxen) compounds. No single mutant was active for all the tested drugs but multiple variants in the library showed high activity with each compound. The high conversions enabled full product characterization that led to the discovery of the new P450 reaction type of oxidative decarboxylation of an α-hydroxy carboxylic acid and the formation a protected imine from an amine, offering a novel route to α-functionalization of amines. The substrate range and varied product profiles suggest that this library of enzymes is a good basis for developing late-stage C-H activation catalysts.